Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038987 · ClinicalTrials.gov registry record · Phase 1
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
NCT00038987: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00038987 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 330 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (450% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038987, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
Study Summary
To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination. To assess the proportion of individuals who respond to vaccination with a "take" (those who form a visible lesion at the injection site) 6 to 8 days after the vaccination.
Interventions
- BIOLOGICAL Wetvax (APSV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2002-05 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00038987 record still lists
NCT00038987 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (450% higher).
The record links to 0 conditions, and to 1 intervention - of which Wetvax (APSV) is the first listed.
NCT00038987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00038987 about?
NCT00038987 is a clinical study titled "Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT". To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination. To assess the proportion of individuals who respond to vaccination with a "take" (those who form a visible les...
What is the current status of trial NCT00038987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2002-05. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00038987?
The interventions under investigation include: Wetvax (APSV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00038987?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00038987's enrollment target sits among peer trials
330 110th of 2000 higher than 1,890 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia